Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
| Revenue | $609,291,000 |
| Net Income | $444,211,000 |
| Free Cash Flow | $-255,699,000 |
| Book Value / Share | N/A |
| Total Liabilities | $9,726,419,000 |
| Total Equity | $9,620,861,000 |
| Debt / Equity | N/A |
| Current Ratio | 3.48 |
| Interest Coverage | N/A |
| Working Capital | N/A |
Core multiples and valuation signals — useful to compare vs peers.
| P/E (TTM) | N/A |
| Industry P/E | N/A |
| Forward P/E | 8.78 |
| P/B | N/A |
| Price / Sales | N/A |
| P / FCF | N/A |
| EV / EBITDA | N/A |
| Graham Number | N/A |
| DCF (placeholder) | — |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Net Margin | N/A |
| ROIC | N/A |
| Asset Turnover | N/A |
| RSI (14) | 73.29 |
| SMA 50 | 40.13 |
| SMA 200 | 36.91 |
| MACD | 1.23 |
| Signal | BULLISH |
| Name | Title |
|---|---|
| Mr. Pablo Legorreta | Founder, Chairman of the Board & CEO (1963) |
| Mr. Terrance P. Coyne | Executive VP & CFO (—) |
| Mr. Christopher Hite | Vice Chairman & Executive VP (1967) |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research & Investments (1976) |
| Mr. Arthur Richard McGivern J.D. | Executive VP & Chief Legal Officer (1975) |
| Mr. Ashwin Pai M.D. | Executive Vice President of Investments (—) |
| Mr. Eric Cornelius Schneider | Senior VP & Chief Technology Officer (—) |
| Dr. James Folmar Reddoch Ph.D. | Executive VP of Investments & Chief Scientific Officer (1971) |
No news available for this company.